Treatment of antineutrophil cytoplasmic antibody-associated vasculitis

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 5, 2012, Pages 447-454

  Rich, Eric N ^a,b   Brown, Kevin K ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

antineutrophil cytoplasmic antibody; Churg Strauss syndrome; granulomatosis with polyangiitis; microscopic polyangiitis; rituximab; vasculitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASE; CHURG STRAUSS SYNDROME; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GRANULOMATOSIS; HEART ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PULMONARY VASCULITIS; QUALITY OF LIFE; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RELAPSE; REMISSION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DISEASE MANAGEMENT; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84864874645     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835701d6     Document Type: Review

References (37)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Arthritis Rheum 1994; 37:187-192.
2. Jennette JC. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis). Clin Exp Immunol 2011; 164 (Suppl. 1):7-10
3. Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 2006; 3:48-57.
4. Mora B, Bosch X. Medical eponyms: time for a name change. Arch Intern Med 2010; 170:1499-1500.
5. Frankel SK, Jayne D. The pulmonary vasculitides. Clin Chest Med 2010; 31:519-536.
6. uillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19-27.
7. Frankel SK, Cosgrove GP, Fischer A, et al. Update in the diagnosis and management of pulmonary vasculitis. Chest 2006; 129:452-465. (Pubitemid 43289869)
8. Luqmani RA, Suppiah R, Grayson PC, et al. Nomenclature and classification of vasculitis-update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS). Clin Exp Immunol 2011; 164 (Suppl. 1):11-13.
9. Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69:1744-1750.
10. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85. (Pubitemid 13217969)
11. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461-2469. (Pubitemid 41117433)
12. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
13. Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
14. Cartin-Ceba R, Fervenza FC, Specks U. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol 2012; 24:15-23.
15. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381-2388.
16. De Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670-680.
17. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71:955-960.
18. Casian A, Jayne D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol 2011; 23:12-17.
19. Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med 2011; 32:335-345.
20. Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188. (Pubitemid 47041083)
21. Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission inWegener's granulomatosis-a clinical randomized controlled trial. Nephrol Dial Transplant 2011; 26:206-213.
22. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2012; 51:634-643.
23. Pagnoux C, Mahr A, Hamidou MA, et al Azathioprine or methotrexate maintenance forANCA-associated vasculitis. NEngl JMed2008;359:2790-2803.
24. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
25. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
26. Matsumoto Y, Sada K-E, Otsuka F, et al. Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients. Rheumatol Int 2011. [Epub ahead of print]
27. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010; 62:1166-1173.
28. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-1400.
29. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-2168.
30. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39:125-130.
31. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:542-548.
32. Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a metaanalysis. Rheumatology 2012; 51:100-109.
33. Suka M, Hayashi T, Kobayashi S, et al. Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study. Mod Rheumatol 2012. [Epub ahead of print].
34. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70:488-494.
35. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011; 63:588-596.
36. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol 2009; 21:41-46.
37. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70:1415-1421.